inactivated split virion trivalent influenza vaccine

The inactivated split virion trivalent influenza vaccine is a biological preparation developed by GlaxoSmithKline (GSK) to provide active immunization against seasonal influenza. This vaccine contains antigens from three distinct influenza virus strains: two influenza A subtypes (typically H1N1 and H3N2) and one influenza B lineage (either Victoria or Yamagata), as selected annually by the World Health Organization. The manufacturing process involves propagating the viruses in embryonated chicken eggs, followed by inactivation with formaldehyde and disruption (splitting) of the viral particles using detergents. This splitting process reduces the risk of systemic reactogenicity while maintaining the immunogenicity of the viral hemagglutinin (HA) and neuraminidase (NA) proteins. Upon administration, the vaccine stimulates the immune system to produce neutralizing antibodies against the HA protein, which prevents the virus from attaching to and entering host respiratory cells, thereby providing protection against infection and severe disease.

Brand names

FluarixFluLaval

Other names

TIVtrivalent inactivated influenza vaccineinfluenza vaccine (split virion, inactivated, trivalent)